Tegavivint triggers TECR-dependent nonapoptotic cancer cell death

Area of Science:

• Biochemistry
• Cell Biology
• Oncology

Background:

• Nonapoptotic cell death mechanisms are crucial for cancer treatment development.
• Identifying novel cell death pathways offers new therapeutic strategies for cancers resistant to conventional therapies.

Purpose of the Study:

• To investigate the mechanism of action of tegavivint, a drug candidate, in inducing cancer cell death.
• To identify the molecular players involved in tegavivint-induced nonapoptotic cell death.

Main Methods:

• Utilized cell-based assays to study cell death induction by tegavivint.
• Investigated the role of lipid metabolism and specific enzymes in the observed cell death.
• Compared the tegavivint-induced cell death pathway with known forms of regulated cell death.

Main Results:

• Tegavivint induces a unique form of nonapoptotic cell death in sarcomas and other cancer cells.
• This cell death mechanism requires the lipid metabolic enzyme trans-2,3-enoyl-CoA reductase (TECR).
• TECR promotes cell death via palmitate synthesis, a saturated long-chain fatty acid, differentiating it from ferroptosis, necroptosis, and pyroptosis.

Conclusions:

• Discovered a novel lipid-dependent nonapoptotic cell death pathway activated by tegavivint.
• TECR plays a critical role in this unique cell death mechanism.
• This finding provides a new therapeutic avenue for cancers treatable with tegavivint.